



OPEN ACCESS

EDITED BY

Alessandro Perrella,
Hospital of the Hills, Italy

REVIEWED BY

Alvaro Mourenza Flórez,
University of Southern California,
United States
Shifu Aggarwal,
Massachusetts General Hospital and Harvard
Medical School, United States

*CORRESPONDENCE

Carla Fontana
✉ carla.fontana@inmi.it

†These authors have contributed equally to
this work

RECEIVED 27 March 2025

ACCEPTED 22 September 2025

PUBLISHED 14 October 2025

CITATION

Messina F, Rotondo C, Ladeira L, Crosetti S,
Properzi M, Dimartino V, Riccitelli B,
Staumont B, Chillemi G, Geris L, Bocci MG
and Fontana C (2025) Molecular exploration
of host-pathogen interactions in severe
Pseudomonas aeruginosa infection through
a multi-level data integration approach.
Front. Med. 12:1600509.
doi: 10.3389/fmed.2025.1600509

COPYRIGHT

© 2025 Messina, Rotondo, Ladeira, Crosetti,
Properzi, Dimartino, Riccitelli, Staumont,
Chillemi, Geris, Bocci and Fontana. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Molecular exploration of host-pathogen interactions in severe *Pseudomonas aeruginosa* infection through a multi-level data integration approach

Francesco Messina^{1†}, Claudia Rotondo^{1†}, Luiz Ladeira²,
Sara Crosetti¹, Michele Properzi¹, Valentina Dimartino¹,
Benedetta Riccitelli¹, Bernard Staumont², Giovanni Chillemi^{3,4},
Liesbet Geris^{2,5,6}, Maria Grazia Bocci^{7†} and Carla Fontana^{1*†}

¹Laboratory of Microbiology and Biobank, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²Biomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium, ³Bioinformatics Research Unit in Infectious Diseases, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ⁴Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, ⁵Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ⁶Biomechanics Section, Department of Mechanical Engineering, KU Leuven, Leuven, Belgium, ⁷Intensive Care Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy

Introduction: Understanding host-pathogen interactions is crucial for explaining the variability in sepsis outcomes, with *Pseudomonas aeruginosa* (PA) remaining a significant public health concern. In this work, we explored PA-human host interaction mechanisms through a data integration workflow, focusing on protein-protein and metabolite-protein interactions, along with pathway modulation in affected organs during severe infections.

Methods: A scoping literature review enabled us to construct a domain-based infection network encompassing pathogenesis concepts, molecular interactions, and host response signatures, providing a wide view of the relevant mechanisms involved in severe bacterial infections.

Results: Our analysis yielded a literature-based comprehensive description of PA infection mechanisms and an annotated dataset of 189 PA-human interactions involving 151 proteins/molecules (109 human proteins, 3 human metabolites, 34 PA proteins, and 5 PA molecules). This dataset was complemented with gene expression analysis from *in vivo* PA-infected lung samples. The results indicated a notable overexpression of proinflammatory pathways and PA-mediated modulation of host lung responses.

Discussion: Our comprehensive molecular network of PA infection represents a valuable tool for the understanding of severe bacterial infections and offers potential applications in predicting clinical phenotypes. Through this approach combining omics data, clinical information, and pathogen characteristics, we have provided a foundation for future research in host-pathogen interactions and the

mechanistic grounds to build dynamic computational models for clinical phenotype predictions.

KEYWORDS

P. aeruginosa, host-pathogen interaction, bacterial infection, disease map, sepsis

Introduction

Sepsis caused by multi-drug resistant pathogens remains a leading cause of mortality in intensive care units (ICU) and represents a significant public health concern (1, 2). While it is established that microbial infection outcomes depend heavily on host conditions and spatial interactions between microbes, hosts, and other microorganisms (3, 4), many molecular details of these complex relationships remain unexplored. *Pseudomonas aeruginosa* (PA) is one of the most common pathogens for nosocomial infections, and, along with *Acinetobacter baumannii* and *Enterobacterales* resistant to carbapenems, it was listed among critical priority pathogens for World Health Organization (5, 6). The European Centre for Disease Prevention and Control (ECDC) has included PA in its antimicrobial resistance surveillance program (7). As an opportunistic human pathogen particularly affecting Cystic Fibrosis (CF) patients, PA's clinical significance stems from multiple drug resistance mechanisms, numerous virulence factors, and biofilm production capabilities, enhancing its infection and host colonization potential (8). Recently, computational approaches have aided in unraveling mechanistic insights of PA infections. A network-assisted experiment allowed the identification of novel genes for virulence and antibiotic resistance, confirmed through experimental validation, showing cross-resistance against multiple drugs due to the same genes (9). In another effort, a real-time deep-learning model was applied to sepsis patients aiming to estimate prognostic outcomes from early infection phases (10). The model addressed baseline acuity, comorbidities, seasonal effects, and secular trends over time, unraveling the strategic significance of computational modeling to improve the clinical outcomes in sepsis patients.

Mechanistic computational modeling, omics data analysis, and clinical research have emerged as crucial tools for bridging the gap between conceptual models and clinical practice in infectious diseases (11, 12). By structuring key pathophysiological mechanisms and identifying conceptual domains, molecular diagrams provide novel insights into biomedical knowledge (11, 13, 14). The value of network-based exploratory and molecular virus-host interactome approaches was particularly evident during the COVID-19 pandemic, where rapid identification of molecular interactions between SARS-CoV-2 and human hosts became crucial to explain the clinical manifestations (15–19), as well as enabled a timely drug repurposing (20, 21). In this context, the resulting molecular maps of disease mechanisms (e.g., a Disease Map)¹ provided

biological meaning to apparently unrelated interactions, facilitating the mechanistic understanding of complex disease processes (22, 23). Following this paradigm, we applied similar strategies to bacterial pathogens such as PA, to uncover actionable insights about complex host interactions in severe systemic infections.

Our study presents a data integration workflow to build a molecular map of interaction between PA and human hosts in severe infection. Through extensive literature review, data curation, and gene expression meta-analysis, we have documented PA infection pathogenic mechanisms, direct protein-protein interactions (PPI), metabolite-protein interactions (MPI), and pathway activations in affected organs, organizing these findings into three conceptual domains: “cellular interaction level”, “tissue interaction level”, and “organ interaction level”.

Materials and methods

Scoping review

We conducted independent literature reviews compliant with international reference guidelines for scoping reviews (24). For each domain, the scoping review outcomes were processed to identify features of PA interactions with the host and the direct or indirect effects that they cause within the host itself.

Using a structured search string in PubMed (Supplementary Text 1), we identified 532 articles after excluding duplicates, non-English publications, and studies not addressing systemic infection or host-pathogen interactions. We supplemented this with 27 additional articles focusing on host response to PA infection in both mouse models and human patients through omics data analysis. During the review process, papers were evaluated in three sequential inclusion criteria: (i) title relevance; (ii) abstract consisting of three conceptual domains, and (iii) identification of specific pathogenic mechanisms in PA infection through full-text analysis. The final selection comprised 150 articles which were categorized into three interaction levels: (1) “cell interaction level”; (2) “tissue interaction level”; and (3) “organ interaction level”. Full-text articles were evaluated by the curators to define the best possible conceptual domains, following the reference methodology (PRISMA-ScR) for the assessment (25, 26). Each article selected for review was independently read and evaluated by two reviewers. At the end of the evaluation, the data results were discussed and evaluated in a specific meeting of the entire working group. Each article was assigned a unique reference ID (SR) and documented in Supplementary Table 1.


¹ <https://disease-maps.io/>

Conceptual domains

First, we identified the conceptual domains that organize the information obtained from the literature, providing a hierarchical model of host-pathogen interaction, following a previous experience on mapping host-pathogen interactions in the COVID-19 Disease Map project (11, 12). Three interaction levels within the host's system were identified: cell, tissue, and organ. For each level, we further identified conceptual domains, describing the interactions with the pathogen (Figure 1). A comprehensive description of all mechanisms and PA-human interactions, along with search string, containing all search terms used in the scoping review section on PubMed, and protein abbreviation were reported in Supplementary Text 1, while a summary can be found below in the results section.

Molecular interaction dataset and human host - PA interactome

We documented PPI and MPI between PA and humans. All interaction details, including type, Uniprot ID, literature reference, and subdomains of the model, were compiled in the curated dataset (Supplementary Table 2). We constructed a network-based interaction model by exploring PA-host data gathered from the scoping review, following methodology established for SARS-CoV-2-human host interactions (16, 17). Human PPI data was retrieved using R packages PSICQUIC and biomaRt (27, 28), resulting in a comprehensive large network of 13,334 nodes and 73,584 interactions that included PA-human host interactions. The mechanisms of infection were estimated using the Random Walk with Restart (RWR) algorithm (29), using each PA protein as a seed and limiting the output to the 200 closest host proteins per PA



protein. Network visualizations were generated using Gephi 0.9.2 (30). Gene set enrichment analysis (GSEA) was performed using the R package *enrichR* (31), testing against Reactome 2022, KEGG 2021 and WikiPathways 2023 human pathways databases (32–34).

Meta-analysis of the whole transcriptome from animal model of PA-induced sepsis

We performed a meta-analysis of gene expression in mouse lung samples comparing *PA*-infected tissues with healthy controls using data from two projects. The first dataset comprised 12 bulk RNAseq samples from *PA*-infected lung tissues (PRJNA975462; GEO: GSE233206, SRA Study SRP439193) (35), while the second included 6 bulk gene expression samples from acute and chronic *PA* pulmonary infection (PRJNA793679; GEO: GSE192890, SRA Study SRP353174) (36). SRA data was processed using Prefetch and converted to FASTQ files using the fastq-dump tool from the SRA Toolkit software v2.11.0 (37, 38). Reads were aligned to the mm10 mouse reference genome using HISAT2 (39). Differentially expressed genes (DEGs) were identified using DESeq2 v.1.42.1 in R version 3.4.3 (40), with thresholds set at $\text{Log}_2\text{FC} > |1|$ and Benjamin-Hochberg False Discovery Rate $< 5\%$ (BH-FDR). To account for batch effects between laboratories, we conducted a meta-analysis using metaRNASeq R packages, combining *p*-values from the two independent RNA-seq experiments using Fisher methods (41). The analysis focused on 21,010 genes shared between datasets, generating combined BH-adjusted *p*-values and average Log_2FC values. Genes meeting the thresholds of $\text{Log}_2\text{FC} > |1|$ and BH FDR $< 5\%$ were classified as DEGs.

Gene enrichment on DEGs in PA infection and healthy conditions

To deliver biological meaning from the data, we performed a gene enrichment analysis using Reactome, KEGG, and WikiPathways (32–34). The *enrichR* R package was used to conduct gene set enrichment analysis, with significance assessed through Fisher exact test (*p*-value) and false discovery rate (*q*-value: adjusted *p*-value for FDR) (31).

Results

Domain-based analysis of PA-human host interactions reveals detailed pathogenic mechanisms

To understand in detail *PA* infection pathogenic mechanisms, we reported many *PA*-human host interactions mechanisms, organizing them into three conceptual domains: cellular, tissue, and organ-level interactions.

At the cellular level, four key aspects characterize *PA*-host interaction: (i) bacterial adhesion/colonization (*PA*-Ad); (ii)

bacterial invasion and innate immune response of the host (*PA*-In); (iii) *PA* exotoxins activity in infection (*PA*-Ex); (iv) bacterial metabolic mechanisms (*PA*-Met). The pathogenic mechanisms in *PA* infection were assigned to each domain (Table 1). *PA* initiates infection through flagellum and type IV pili adherence, interacting with MUC1 ectodomains via NEU1 modulation (42, 43). The bacterium employs multiple adhesion strategies, including biofilm formation, psl adhesins (44, 45), and various receptors binding to extracellular matrix components (46, 47). During invasion, *PA* modifies host cell membranes through PI3K/PIP3/Akt pathway activation and uses specialized proteins like piliY1 for binding (48). The bacterium's survival in macrophages relies on *mgtC* and *oprF* (49). The exotoxin family (*exoS*, *exoT*, *exoU*, *exoY*, *exoA*) facilitates pathogenesis through various mechanisms, including protein ribosylation, cytoskeleton modification, and membrane disruption (50–53).

At the tissue level, *PA* affects three primary domains: (i) endothelial tissue (Endothelial Tissue - EnT); (ii) lower airway and alveolar epithelial tissue in the lung, including CF conditions (Airway Epithelial Tissue - AET); and (iii) other epithelial tissues such as desquamated bronchial and urinary epithelia (Other Epithelial Tissues - ETs). In endothelial tissue, particularly during severe infection, APOE exhibits antibacterial activity (54), while T3SS affects actin cytoskeleton dynamics (55). The bacterium adapts to blood survival by regulating metabolic pathways and virulence factors (56, 57). In airway epithelial tissue, particularly relevant in CF conditions, *PA* flagella binds to asialoGM1 and MUC1, triggering inflammatory responses (43, 58, 59). CFTR plays a crucial role in *PA* uptake and inflammation (60, 61). In other epithelial tissues, *PA* binds through HSPGs and N-glycans (62), with quorum sensing molecules affecting barrier integrity (63).

Finally, at the organ level, *PA* infection primarily impacts the lung and bloodstream. In lung infections, particularly in CF, *PA* causes intense inflammation with neutrophil infiltration and cytokine production, inducing changes in immune cell composition (36, 59, 64). The infection involves various immune mechanisms, including TRPV4 (65), TIM3/Gal-9 signaling (64), and NET formation (66). In bloodstream infections, *PA* induces differential immune cell responses and affects the vascular endothelium through multiple mechanisms, such as TREM-1 (67–69). The Hxu system contributes significantly to bloodstream infection capability (70). These multi-level interactions highlight the complexity of *PA* pathogenesis and its adaptive capabilities in different host environments.

PA-host proteins interaction network reveals key mechanisms modulated in humans by PA severe infection

To reveal key molecular mechanisms in *PA* severe infection, we collected the molecular interactions between *PA* and human proteins during different infection stages, which were manually curated. Analysis of 92 articles revealed multiple direct protein-protein interactions (PPI) and molecule-protein interactions (MPI), detailed in Supplementary Table 2 and annotated with Uniprot IDs, references, and model subdomains.

TABLE 1 The table summarizes the main pathogenic mechanisms in *PA* infection for each domain, with comprehensive conceptual analysis provided in the [Supplementary Text 1](#): (A) cell interaction level; (B) tissue interaction level; (C) organ interaction level. This structured approach enabled us to characterize specific mechanisms and experimental models of *PA* infections.

Domain	Subdomain	Key molecules	Biological outcome	References
Cell interaction level	<i>PA</i> Adhesion/colonization	Flagellum, pilA	Adherence in upper respiratory tract, interaction with IRF-1	(42, 43, 71)
		Flagellum, NEU1	Modulation of binding between flagellum and MUC1	(43, 71)
		Pilus	Interaction with asialo-GM1, asialo-GM2, glycosphingolipids; MMP7 expression induction	(58, 72–74)
		Psl	Biofilm formation, cell adhesion, flagellin-mediated NF- κ B activation	(45)
		estA, oprD, oprG, oprQ, PA3923, Paf	Binding to LAMA1 (α 4, α 5) and FN1	(46, 47)
		lecA	Binding to Gb3 and GPI- anchored CD59	(75)
		CD18, N-glycans	<i>PA</i> uptake facilitation via integrin-mediated uptake	(76)
	<i>PA</i> Invasion	mgtC, oprF	Macrophage survival	(49)
		Flagellin	EGFR/TGF- α release, MUC1 phosphorylation, TLR5 association	(77)
		IMPa	Leukocyte rolling adhesion via CD43, CD44, CD55, PSGL-1	(78)
		pumA	NF- κ B inhibition, interaction with TIRAP, MyD88, UBAP1	(79)
		LPS	SP-A interaction, TNF- α release limitation	(80)
		LL-37	IL-8 production inhibition, mucA mutagenesis	(81, 82)
		lasB	Protein degradation (elastin, collagen, laminin, IgG, C3, α 1-AT, IFN- γ , IL-2)	(83)
		LPS	MUC5AC overproduction	(84)
		CD95/CD95 ligand	Apoptosis triggering, NF- κ B/JNKs/GADD153/PLA 2 stimulation	(85)
		PTEN-CFTR complex	<i>PA</i> intracellular killing promotion	(86)
	Exotoxins	Azurin	Cell proliferation inhibition via aldolase A secretion	(87)
		3OC12-HSL	T-lymphocyte proliferation inhibition, MAPK-p38 activation	(88)
		PAI-1	Cyclooxygenase 2 activation in fibroblasts and ECs	(89)
		PNC	Neutrophil death, mitochondrial dysfunction, IL-8 downregulation	(51, 90, 91)
		pvrA	PC and fatty acid catabolism regulation	(92)
Tissue interaction level	Endothelial tissue	APOE3	NF- κ B reduction in monocytes, antibacterial activity	(54)
		exoS, exoT	Lim kinase-cofilin pathway modulation, GTPase inactivation	(55)
		lasB/pseudolysin	Endothelial adherence disruption, cytotoxicity	(67)
	Airway epithelial tissue	pilY1	PI3K/PIP3/Akt pathway activation, membrane remodeling	(48)
		Flagella	TLR5 activation, neutrophil respiratory burst	(59, 93)
		pilA	Tight junction disruption, IRF-1 activation	(67, 94–96)

(Continued)

TABLE 1 (Continued)

Domain	Subdomain	Key molecules	Biological outcome	References
		exoA	ADAM10 interaction, leukocyte migration alteration	(97)
		PNC	Ciliary dysfunction, mucus velocity alteration	(98)
		PA-IL, PA-IIL	Cilia binding, airway infection facilitation	(99)
		lasB	EC detachment via FN1/vWf degradation	(47)
		Vav3	b1 integrin/FN1 complex formation in CF	(100)
		CFTR	PA uptake regulation, NF- κ B activation	(60, 61)
		Various	IL-6/CXCL8/TACE expression induction	(101)
	Other epithelial tissues	HSPGs	Enhanced apical surface binding	(62)
		pilA, Flagella	N-glycan and HSPG-mediated binding	(62)
		T3SS, LPS	Barrier function disruption	(63)
		exoS	Na/K-ATPase inhibition via FXYD3	(102)
		T3SS components	Keratitis development, tight junction disruption	(96)
		Fur regulator	Iron acquisition pathway regulation	(103)
Organ interaction level	Lungs	LPS, CFTR	PA uptake, NF- κ B activation	(59, 104), (64)
		CFTR/TLR4/TLR5	Phagocytosis regulation, inflammatory response	(59, 60)
		TRPV4	Immune defense enhancement	(65)
		Elastase	IgG cleavage, phagocytosis inhibition	(105)
		LL-37, CLEC5A	NET formation, cytokine release	(66)
		MIF	Lung inflammation reduction	(72)
		Various	Altered immune cell composition, pathway regulation	(35, 36),
		–	Gut microbiota metabolism disruption	(106)
	Bloodstream	TREM-1	Inflammatory response modulation	(69)
		QS genes, pqsH	Systemic infection adaptation	(107)
		Hxu system	BSI pathogenesis regulation	(70)
		–	Blood metabolome alteration	(108)
		–	Differential immune cell response	(68)

We identified 151 molecules: 109 human proteins, 3 human metabolites (Gangliotetraosylceramide, Phospholipid cell membrane, glycosphingolipid globotriaosylceramide),

34 PA proteins, and 5 PA molecules (3O-C12-HSL, LipidA, LPS, Exopolysaccharide, Pyocyanin), yielding 189 PA-human interactions and 7 human-human interactions. Note that the




FIGURE 2

Network of PA-human host molecular interactions, with the top 200 nearest proteins found by the Random Walk with Restart (RWR) algorithm. Nodes have different colors to show different kinds of molecules: purple, human proteins; green, PA proteins; light blue, PA molecules; orange, human proteins belonging to the complement pathway.

189 interactions include multiple events involving the same molecules, while the 151 components represent unique entities within the network.

These interactions were categorized into four cellular domains: Adhesion process (PA-Ad), invasion and injury of tissue (PA-Inv), exotoxin production (PA-Ex) and bacterial metabolism (PA-Meta).

Gene enrichment analysis revealed significant pathway associations across Reactome, WikiPathways and KEGG (Supplementary Table 3). Notable enrichments included the “Pathogenic *Escherichia coli* Infection WP2272” pathway (WikiPathways) and “Pertussis” (KEGG) with FDR < 0.0001%. Reactome analysis highlighted three significant pathways (FDR < 0.0001%), including Programmed Cell Death R-HSA-5357801, Toll-like Receptor Cascades R-HSA-168898, and Signaling by Interleukins R-HSA-449147. In these pathways several key proteins (e.g., exoS and exoT) would play a modulating

role, such as inhibition of interleukin proteins or degradation of occludin (OCLN), a cell death regulator (109).

A full network of interactions between PA and human host proteins (Figure 2) enabled us to reveal the overall cell response to infection, digging up also new possible pathogenic mechanisms: the modulating effect of outer membrane proteins oprH, oprQ, and the elastase lasB on Complement Cascade Pathway (Reactome R-HSA-166658; 18/55; FDR < 0.0001%) for contrasting bacterial cell damage. These proteins also showed significant interactions with blood clotting factors, such as VWF, SERPINF2, PLAUR, PLAT, and PLG (Complement and Coagulation Cascade WP558; 20/58; FDR < 0.0001%), suggesting a potential involvement in thrombotic event. Furthermore, the role of exotoxin (exoS, exoY, and exoT) in PA infection proved central to triggering of cell toxicity through interactions with cytoplasmic 14-3-3 proteins (e.g., YWHAB).




FIGURE 3

GSEA with WikiPathways (a) and Reactome (b), based on upregulated DEGs in *PA*-infected samples, obtained from meta-analysis of two infection experiments in mouse lung tissues.

Meta-analysis of whole transcriptome of *PA*-infected lung tissues from mice reveals selective modulation of pro-inflammatory pathways

To better define the biological response in *PA*-infected lung tissues, we carried out a meta-analysis of gene expression of two bulk RNAseq datasets (GSE233206 and GSE192890) comparing *PA*-infected mice lung samples with healthy controls. Our meta-analysis identified 1,560 upregulated and 383 downregulated genes ($\text{Log}_2\text{FC} > 1$; $\text{FDR BH} < 5\%$, [Supplementary Table 4](#)). Pathway analysis of upregulated genes using WikiPathways revealed significant enrichment in inflammation-related pathways, notably “Overview of Proinflammatory and Profibrotic Mediators WP5095” (39/129, $\text{FDR} < 0.0001\%$). Reactome analysis aligned with our scoping review findings, highlighting significant enrichment ($\text{FDR} < 0.000001\%$) in key pathways: Cytokine

Signaling in Immune System R-HSA-1280215 (145/702), Signaling by Interleukins R-HSA-449147 (109/453), Interleukin-10 Signaling R-HSA-6783783 (31/45) ([Figures 3a, b](#)). Proinflammatory pathways were found nested into Interleukins R-HSA-449147 (*Homo sapiens*) Reactome’s entry (Interleukin-2 family signaling R-HSA-451927; Interleukin-3, Interleukin-5 and GM-CSF signaling R-HSA-512988; Interferon alpha/beta signaling R-HSA-909733; Interferon gamma signaling R-HSA-877300; ISG15 antiviral mechanism (*Homo sapiens*) R-HSA-1169408; PKR-mediated signaling R-HSA-9833482; TNFR2 non-canonical NF-κB pathway R-HSA-5668541; Signaling by CSF1 (M-CSF) in myeloid cells; R-HSA-9680350. All these pathways have many key proteins for *PA* infection, which are described as targets for *PA* exoU, exoS, azu, lasB, aprA, oprF, pilA, and LPS. These results suggest that these pathways are directly involved in initiating the innate response to *PA* infection, but also highlight the potential role of *PA* molecules in modulating and limiting this response, particularly for interleukin signaling.

Discussion

In this work, we present the development of a comprehensive data integration model to understand *PA* infection through detailed exploration of the literature and metanalysis of transcriptomics datasets, identifying specific human molecular targets for each *PA* molecule, pathogenic mechanisms, and host responses. In general, *PA* could be considered a useful example for studying severe systemic infections, given its multi-drug resistance capabilities, ability to cause acute and chronic infections in pulmonary disease patients, and its capacity to form biofilm in hypoxic conditions, which makes it extremely difficult to treat (110, 111).

Firstly, the central role of *exoS* during infection was confirmed, while enhanced activity among *exo* family proteins, including *exoY* and *exoT*, was widely highlighted (112). *ExoS* functions by inhibiting several proteins of interleukin pathways and inducing the degradation of Occludin (OCLN), an integral membrane protein involved in cytokine-induced regulation of the tight junction permeability barrier, ultimately inducing cell death (67). Through its ADP RT activity, *exoS* modulates host cell apoptosis, inducing *PA*-infected cell death by targeting various Ras proteins (113). The Complement Cascade Pathway undergoes modulation by *PA*'s outer membrane proteins, *oprH*, *oprQ*, and elastase *lasB*, which trigger cytotoxic effects and adhesion through complement binding, particularly C3 (114). This result mirrors the mechanism of activation of the complement system, in which C3 is the main actor against bacteria, through a link with *oprF*, a porin involved in ion transport (Na⁺ and Cl[−]) and anaerobic biofilm production (115, 116). A significant finding was the interaction between *oprH*, *oprQ*, and *lasB* with coagulation proteins, suggesting their involvement in thrombotic processes. *PA* *lasB*'s cleavage of a C-terminal peptide FYT21 derived from thrombin inhibits activation of the transcription factors NFκ-B and activator protein 1 (AP-1). *PA* demonstrates sophisticated modulation of host immune responses through multiple pathways; *aprA*, *lasB*, and *exoS* exhibit inhibitory effects on interleukin pathways (112, 117, 118), indicating an adaptive modulation that enhances *PA* survival within the host. Such an effect was confirmed in *PA* infection, where *PA*-derived DnaK negatively regulates IL-1β production by cross-talk between JNK and PI3K/PDK1/FoxO1 pathways (119). Notably, decreased *PA* levels in CF patients correlate with reduced proinflammatory cytokines (120).

Our findings provided a broader view of molecular perturbations in *PA* systemic infection and served as a foundation for developing specific disease maps for severe *PA* infection, supporting the integration of omics data from clinical cases into predictive computational models. Future developments may incorporate text mining and AI-assisted analysis for drug target identification (23) and digital modeling of the human immune system under infection conditions (121) to better predict real patient outcomes and test potential therapeutic strategies in a personalized fashion.

There are some limitations worth noting. While we have documented numerous significant *PA*-human interactions, our model may not encompass all possible interactions. The PPI/MPI dataset requires iterative updates to incorporate new experimental findings from both *in vitro*, *in vivo* and clinical studies.

Furthermore, since our interaction data derives primarily from *in vitro* experiments, the described pathogenic mechanisms require validation in the context of severe systemic infections. Finally, our differential expression meta-analysis, conducted in mouse models with limited sample size, provides an overview of host gene-expression signatures in *PA* infection but requires confirmation through clinical data.

In conclusion, our study provides a comprehensive collection and analysis of molecular mechanisms in *P. aeruginosa* infection, combining literature-based evidence, protein-protein interaction analysis, and transcriptomic data from *in vivo* studies. A detailed dataset of *PA*-host interactions across cellular, tissue, and organ levels was built through a systematic data integration approach. Our findings highlight the complex interplay between *PA* virulence factors and host responses, particularly the role of *exoS* in modulating interleukin pathways and the involvement of outer membrane proteins in the complement cascade. The integration of differential expression analysis from mouse models further strengthens our understanding of host response patterns, particularly in proinflammatory and immune signaling pathways. As antimicrobial resistance continues to pose significant challenges in healthcare, such a comprehensive molecular understanding may prove invaluable for applying precision medicine approaches to severe bacterial infections and improving patient-tailored treatments in severe systemic infections.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Author contributions

FM: Conceptualization, Data curation, Investigation, Software, Supervision, Writing – original draft, Writing – review & editing. CR: Data curation, Formal analysis, Methodology, Validation, Writing – review & editing. LL: Data curation, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. SC: Data curation, Methodology, Software, Writing – review & editing. MP: Data curation, Formal analysis, Methodology, Writing – review & editing. VD: Data curation, Formal analysis, Methodology, Writing – review & editing. BR: Data curation, Formal analysis, Methodology, Writing – review & editing. BS: Formal analysis, Supervision, Validation, Writing – review & editing. GC: Formal analysis, Methodology, Validation, Writing – review & editing. LG: Funding acquisition, Resources, Supervision, Writing – review & editing. MB: Formal analysis, Supervision, Validation, Writing – review & editing. CF: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by grants from the Italian Ministry of Health through “Ricerca Corrente” Linea 3 Project 2 and “5 per 1000–2021” grant of the Italian Ministry of Health (grant no. 5M-2021-23683787) (FM) and the European Commission with the HORIZON program BY-COVID (grant no. 101046203–BY-COVID). Moreover, the authors acknowledge funding from the European Union’s Horizon 2020 research and innovation program via the European Research Council (ERC CoG INSITE 772418).

Acknowledgments

Figure 1 has been designed using resources from [Flaticon.com](https://flaticon.com).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

- Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-resistant sepsis: a critical healthcare challenge. *Antibiotics*. (2024) 13:46. doi: 10.3390/antibiotics13010046
- Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: a review of advances in management. *Adv Ther*. (2017) 34:2393–411. doi: 10.1007/s12325-017-0622-8
- Saarenpää S, Shalev O, Ashkenazy H, Carlos V, Lundberg DS, Weigel D, et al. Spatial metatranscriptomics resolves host-bacteria-fungi interactomes. *Nat Biotechnol*. (2023) 42:1384–93. doi: 10.1038/s41587-023-01979-2
- Mu A, Klare WP, Baines SL, Ignatius Pang CN, Guerillot R, Harbison-Price N, et al. Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria. *Nat Commun*. (2023) 14:1530. doi: 10.1038/s41467-023-37200-w
- WHO. *WHO Publishes list of Bacteria For Which New Antibiotics Are Urgently Needed*. Basel: World Health Organization (2022).
- WHO. *Pathogens Prioritization: a Scientific Framework for Epidemic and Pandemic Research Preparedness*. Basel: World Health Organization (2024).
- ECDC. *Antimicrobial Resistance Surveillance in Europe 2022*. Stockholm: ECDC (2022).
- Dahal S, Renz A, Dräger A, Yang L. Genome-scale model of *Pseudomonas aeruginosa* metabolism unveils virulence and drug potentiation. *Commun Biol*. (2023) 6:165. doi: 10.1038/s42003-023-04540-8
- Hwang S, Kim CY, Ji SG, Go J, Kim H, Yang S, et al. Network-assisted investigation of virulence and antibiotic-resistance systems in *Pseudomonas aeruginosa*. *Sci Rep*. (2016) 6:26223. doi: 10.1038/srep26223
- Boussina A, Shashikumar SP, Malhotra A, Owens RL, El-Kareh R, Longhurst CA, et al. Impact of a deep learning sepsis prediction model on quality of care and survival. *NPJ Digit Med*. (2024) 7:14. doi: 10.1038/s41746-023-00986-6
- Singh V, Naldi A, Soliman S, Niarakis A. A large-scale Boolean model of the rheumatoid arthritis fibroblast-like synoviocytes predicts drug synergies in the arthritic joint. *NPJ Syst Biol Appl*. (2023) 9:33. doi: 10.1038/s41540-023-00294-5
- Montaldo C, Messina F, Abbate I, Antonioli M, Bordoni V, Aiello A, et al. Multi-omics approach to COVID-19: a domain-based literature review. *J Transl Med*. (2021) 19:501. doi: 10.1186/s12967-021-03168-8
- Hemedan AA, Niarakis A, Schneider R, Ostaszewski M. Boolean modelling as a logic-based dynamic approach in systems medicine. *Comput Struct Biotechnol J*. (2022) 20:3161–72. doi: 10.1016/j.csbj.2022.06.035
- Ostaszewski M, Mazein A, Gillespie ME, Kuperstein I, Niarakis A, Hermjakob H, et al. COVID-19 disease map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. *Sci Data*. (2020) 7:e10136. doi: 10.1038/s41597-020-0477-8
- Steiner S, Kratzel A, Barut GT, Lang RM, Aguiar Moreira E, Thomann L, et al. SARS-CoV-2 biology and host interactions. *Nat Rev Microbiol*. (2024) 22:206–25. doi: 10.1038/s41597-023-01003-z
- Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, et al. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med*. (2020) 18:233. doi: 10.1186/s12967-020-02405-w
- Messina F, Giombini E, Montaldo C, Sharma AA, Zoccoli A, Sekaly RP, et al. Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2-host interactome. *Cell Death Dis*. (2021) 12:788. doi: 10.1038/s41419-021-03881-8
- Schmidt N, Lareau CA, Keshishian H, Ganskih S, Schneider C, Hennig T, et al. The SARS-CoV-2 RNA-protein interactome in infected human cells. *Nat Microbiol*. (2021) 6:339–53. doi: 10.1038/s41564-020-00846-z
- Lee S, Lee YS, Choi Y, Son A, Park Y, Lee KM, et al. The SARS-CoV-2 RNA interactome. *Mol Cell*. (2021) 81:2838–50.e6. doi: 10.1016/j.molcel.2021.04.022
- Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*. (2020) 583:459–68. doi: 10.1038/s41586-020-2286-9

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmed.2025.1600509/full#supplementary-material>

21. Zhou Y, Liu Y, Gupta S, Paramo MI, Hou Y, Mao C, et al. A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets. *Nat Biotechnol.* (2023) 41:128–39. doi: 10.1038/s41587-022-01474-0
22. Ostaszewski M, Niarakis A, Mazein A, Kuperstein I, Phair R, Orta-Resendiz A, et al. COVID-19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms. *Mol Syst Biol* (2021) 17:e10387. doi: 10.15252/msb.202110387
23. Niarakis A, Ostaszewski M, Mazein A, Kuperstein I, Kutmon M, Gillespie ME, et al. Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches. *Front Immunol.* (2023) 14:1282859. doi: 10.3389/fimmu.2023.1282859
24. Peters MD, Godfrey CM, Khalil H, Mcinerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. *Int J Evid Based Healthc.* (2015) 13:141–6. doi: 10.1097/XEB.0000000000000050
25. Peterson JW. Bacterial pathogenesis. 4th ed. In: Baron S editor. *Medical Microbiology*. Galveston, TX: University of Texas Medical Branch at Galveston (1996).
26. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med.* (2018) 169:467–73. doi: 10.7326/M18-0850
27. Aranda B, Blankenburg H, Kerrien S, Brinkman FS, Ceol A, Chautard E, et al. PSICQUIC and PSISCORE: accessing and scoring molecular interactions. *Nat Methods.* (2011) 8:528–9. doi: 10.1038/nmeth.1637
28. Smedley D, Haider S, Ballester B, Holland R, London D, Thorisson G, et al. BioMart—biological queries made easy. *BMC Genomics.* (2009) 10:22. doi: 10.1186/1471-2164-10-22
29. Valdeolivas A, Tichit L, Navarro C, Perrin S, Odellin G, Levy N, et al. Random walk with restart on multiplex and heterogeneous biological networks. *Bioinformatics.* (2019) 35:497–505. doi: 10.1093/bioinformatics/bty637
30. Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. In: *Proceedings of the International AAAI Conference on Web and Social Media.* (2009) p. 361–362. doi: 10.1609/icwsm.v3i1.13937
31. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* (2016) 44:W90–7. doi: 10.1093/nar/gkw377
32. Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. *Nucleic Acids Res.* (2024) 52:D672–8. doi: 10.1093/nar/gkz1031
33. Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic Acids Res.* (2018) 46:D661–7. doi: 10.1093/nar/gkx1064
34. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* (2017) 45:D353–61. doi: 10.1093/nar/gkw1092
35. Yang Y, Ma T, Zhang J, Tang Y, Tang M, Zou C, et al. An integrated multi-omics analysis of identifies distinct molecular characteristics in pulmonary infections of *Pseudomonas aeruginosa*. *PLoS Pathog.* (2023) 19:e1011570. doi: 10.1371/journal.ppat.1011570
36. Hu X, Wu M, Ma T, Zhang Y, Zou C, Wang R, et al. Single-cell transcriptomics reveals distinct cell response between acute and chronic pulmonary infection of *Pseudomonas aeruginosa*. *MedComm.* (2022) 3:e193. doi: 10.1002/mco2.193
37. Leinonen R, Sugawara H, Shumway M. The sequence read archive. *Nucleic Acids Res.* (2011) 39:D19–21. doi: 10.1093/nar/gkq1019
38. Han Z, Hua J, Xue W, Zhu F. Integrating the ribonucleic acid sequencing data from various studies for exploring the multiple sclerosis-related long noncoding ribonucleic acids and their functions. *Front Genet.* (2019) 10:1136. doi: 10.3389/fgene.2019.01136
39. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Methods.* (2015) 12:357–60. doi: 10.1038/nmeth.3317
40. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* (2014) 15:550. doi: 10.1186/s13059-014-0550-8
41. Rau A, Marot G, Jaffrezic F. Differential meta-analysis of RNA-seq data from multiple studies. *BMC Bioinformatics.* (2014) 15:91. doi: 10.1186/1471-2105-15-91
42. Hyun SW, Liu A, Liu Z, Cross AS, Verceles AC, Magesh S, et al. The NEU1-selective sialidase inhibitor, C9- butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo. *Glycobiology.* (2016) 26:834–49. doi: 10.1093/glycob/cwv060
43. Hyun SW, Imamura A, Ishida H, Piepenbrink KH, Goldblum SE, Lillehoj EP. The sialidase NEU1 directly interacts with the juxtamembranous segment of the cytoplasmic domain of mucin-1 to inhibit downstream PI3K-Akt signaling. *J Biol Chem.* (2021) 297:101337. doi: 10.1016/j.jbc.2021.101337
44. Kaya E, Grassi L, Benedetti A, Maisetta G, Pileggi C, Di Luca M, et al. In vitro interaction of *Pseudomonas aeruginosa* biofilms with human peripheral blood mononuclear cells. *Front Cell Infect Microbiol.* (2020) 10:187. doi: 10.3389/fcimb.2020.00187
45. Byrd MS, Pang B, Mishra M, Swords WE, Wozniak DJ. The *Pseudomonas aeruginosa* exopolysaccharide Psl facilitates surface adherence and NF-kappaB activation in A549 cells. *mBio.* (2010) 1:e140–110. doi: 10.1128/mBio.00140-10
46. Paulsson M, Su YC, Ringwood T, Udden F, Riesbeck K. *Pseudomonas aeruginosa* uses multiple receptors for adherence to laminin during infection of the respiratory tract and skin wounds. *Sci Rep.* (2019) 9:18168. doi: 10.1038/s41598-019-54622-z
47. Beaufort N, Corvazier E, Manaoindrou S, De Bentzmann S, Pidard D. Disruption of the endothelial barrier by proteases from the bacterial pathogen *Pseudomonas aeruginosa*: implication of matrilysin and receptor cleavage. *PLoS One* (2013) 8:e75708. doi: 10.1371/journal.pone.0075708
48. Engel J, Eran Y. Subversion of mucosal barrier polarity by *pseudomonas aeruginosa*. *Front Microbiol.* (2011) 2:114. doi: 10.3389/fmicb.2011.00114
49. Garai P, Berry L, Moussouni M, Bleves S, Blanc-Potard AB. Killing from the inside: Intracellular role of T3SS in the fate of *Pseudomonas aeruginosa* within macrophages revealed by mgtC and oprF mutants. *PLoS Pathog.* (2019) 15:e1007812. doi: 10.1371/journal.ppat.1007812
50. Henriksson ML, Rosqvist R, Telepnev M, Wolf-Watz H, Hallberg B. Ras effector pathway activation by epidermal growth factor is inhibited in vivo by exoenzyme S ADP- ribosylation of Ras. *Biochem J.* (2000) 347:217–22.
51. Ghatak S, Hemann C, Boslett J, Singh K, Sharma A, El Masry MS, et al. Bacterial pyocyanin inducible keratin 6A accelerates closure of epithelial defect under conditions of mitochondrial dysfunction. *J Invest Dermatol.* (2023) 143:2052–64.e5. doi: 10.1016/j.jid.2023.03.1671
52. Jia J, Alaoui-El-Azher M, Chow M, Chambers TC, Baker H, Jin S. c-Jun NH2-terminal kinase-mediated signaling is essential for *Pseudomonas aeruginosa* ExoS-induced apoptosis. *Infect Immun.* (2003) 71:3361–70. doi: 10.1128/IAI.71.6.3361-3370.2003
53. Krall R, Schmidt G, Aktories K, Barbieri JT. *Pseudomonas aeruginosa* ExoT is a Rho GTPase-activating protein. *Infect Immun.* (2000) 68:6066–8. doi: 10.1128/IAI.68.10.6066-6068.2000
54. Puthia M, Marzinek JK, Petruk G, Erturk Bergdahl G, Bond PJ, Petrlova J. Antibacterial and anti-inflammatory effects of apolipoprotein E. *Biomedicines.* (2022) 10:1430. doi: 10.3390/biomedicines10061430
55. Huber P, Bouillot S, Elsen S, Attree I. Sequential inactivation of Rho GTPases and Lim kinase by *Pseudomonas aeruginosa* toxins ExoS and ExoT leads to endothelial monolayer breakdown. *Cell Mol Life Sci.* (2014) 71:1927–41. doi: 10.1007/s00018-013-1451-9
56. Turner KH, Everett J, Trivedi U, Rumbaugh KP, Whiteley M. Requirements for *Pseudomonas aeruginosa* acute burn and chronic surgical wound infection. *PLoS Genet.* (2014) 10:e1004518. doi: 10.1371/journal.pgen.1004518
57. Elmassy MM, Mudaliar NS, Kottapalli KR, Dissanaik S, Griswold JA, San Francisco MJ, et al. *Pseudomonas aeruginosa* alters its transcriptome related to carbon metabolism and virulence as a possible survival strategy in blood from trauma patients. *mSystems.* (2019) 4:e312–8. doi: 10.1128/mSystems.00312-18
58. Adamo R, Sokol S, Soong G, Gomez MI, Prince A. *Pseudomonas aeruginosa* flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. *Am J Respir Cell Mol Biol.* (2004) 30:627–34. doi: 10.1165/rmb.2003-0260OC
59. Blohmke CJ, Park J, Hirschfeld AF, Victor RE, Schneiderman J, Stefanowicz D, et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. *J Immunol.* (2010) 185:7731–8. doi: 10.4049/jimmunol.1001513
60. Haensch MD, Ciche TA, Luckie DB. *Pseudomonas* or LPS exposure alters CFTR iodide efflux in 2WT2 epithelial cells with time and dose dependence. *Biochem Biophys Res Commun.* (2010) 394:1087–92. doi: 10.1016/j.bbr.2010.03.131
61. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, et al. CFTR is a pattern recognition molecule that extracts *Pseudomonas aeruginosa* LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. *Proc Natl Acad Sci U S A.* (2002) 99:6907–12. doi: 10.1073/pnas.092160899
62. Bucior I, Pielage JF, Engel JN. *Pseudomonas aeruginosa* pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. *PLoS Pathog.* (2012) 8:e1002616. doi: 10.1371/journal.ppat.1002616
63. Vikstrom E, Bui L, Konradsson P, Magnusson KE. The junctional integrity of epithelial cells is modulated by *Pseudomonas aeruginosa* quorum sensing molecule through phosphorylation-dependent mechanisms. *Exp Cell Res.* (2009) 315:313–26. doi: 10.1016/j.yexcr.2008.10.044
64. Vega-Carrascal I, Bergin DA, McElvaney OJ, McCarthy C, Banville N, Pohl K, et al. Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. *J Immunol.* (2014) 192:2418–31. doi: 10.4049/jimmunol.1300711
65. Scheraga RG, Abraham S, Grove LM, Southern BD, Crish JF, Perelas A, et al. TRPV4 protects the lung from bacterial pneumonia via MAPK molecular pathway switching. *J Immunol.* (2020) 204:1310–21. doi: 10.4049/jimmunol.1901033
66. Sung PS, Peng YC, Yang SP, Chiu CH, Hsieh SL. CLEC5A is critical in *Pseudomonas aeruginosa*-induced NET formation and acute lung injury. *JCI Insight.* (2022) 7:e156613. doi: 10.1172/jci.insight.156613

67. Soong G, Parker D, Magargee M, Prince AS. The type III toxins of *Pseudomonas aeruginosa* disrupt epithelial barrier function. *J Bacteriol.* (2008) 190:2814–21. doi: 10.1128/JB.01567-07
68. Oelen R, De Vries DH, Brugge H, Gordon MG, Vochteloo M, Ye CJ, et al. Single-cell RNA-sequencing of peripheral blood mononuclear cells reveals widespread, context-specific gene expression regulation upon pathogenic exposure. *Nat Commun.* (2022) 13:3267. doi: 10.1038/s41467-022-30893-5
69. Gibot S, Jolly L, Lemarie J, Carrasco K, Derive M, Boufenzar A. Triggering receptor expressed on myeloid cells-1 inhibitor targeted to endothelium decreases cell activation. *Front Immunol.* (2019) 10:2314. doi: 10.3389/fimmu.2019.02314
70. Yang F, Zhou Y, Chen P, Cai Z, Yue Z, Jin Y, et al. High-level expression of cell-surface signaling system hxx enhances *Pseudomonas aeruginosa* bloodstream infection. *Infect Immun.* (2022) 90:e0032922. doi: 10.1128/iai.00329-22
71. Lory S, Ichikawa JK. *Pseudomonas*-epithelial cell interactions dissected with DNA microarrays. *Chest.* (2002) 121:36S–9S. doi: 10.1378/chest.121.3_suppl.36S
72. Tynan A, Mawhinney L, Armstrong ME, O'reilly C, Kennedy S, Caraher E, et al. Macrophage migration inhibitory factor enhances *Pseudomonas aeruginosa* biofilm formation, potentially contributing to cystic fibrosis pathogenesis. *FASEB J.* (2017) 31:5102–10. doi: 10.1096/fj.201700463R
73. Hsieh JC, Tham DM, Feng W, Huang F, Embaie S, Liu K, et al. Intranasal immunization strategy to impede pilin-mediated binding of *Pseudomonas aeruginosa* to airway epithelial cells. *Infect Immun.* (2005) 73:7705–17. doi: 10.1128/IAI.73.11.7705-7717.2005
74. Wong WY, Campbell AP, McInnes C, Sykes BD, Paranchych W, Irvin RT, et al. Structure-function analysis of the adherence-binding domain on the pilin of *Pseudomonas aeruginosa* strains PAK and KB7. *Biochemistry.* (1995) 34:12963–72. doi: 10.1021/bi00040a006
75. Brandel A, Aigal S, Lagies S, Schlimpert M, Melendez AV, Xu M, et al. The Gb3-enriched CD59/flotillin plasma membrane domain regulates host cell invasion by *Pseudomonas aeruginosa*. *Cell Mol Life Sci.* (2021) 78:3637–56. doi: 10.1007/s00018-021-03766-1
76. Demirdjian S, Hopkins D, Cumbal N, Lefort CT, Berwin B. Distinct contributions of CD18 integrins for binding and phagocytic internalization of *Pseudomonas aeruginosa*. *Infect Immun.* (2020) 88:e00011–20. doi: 10.1128/IAI.00011-20
77. Kato K, Lillehoj EP, Kim KC. *Pseudomonas aeruginosa* stimulates tyrosine phosphorylation of and TLR5 association with the MUC1 cytoplasmic tail through EGFR activation. *Inflamm Res.* (2016) 65:225–33. doi: 10.1007/s00011-015-0908-8
78. Bardoel BW, Van Kessel KP, Van Strijp JA, Milder FJ. Inhibition of *Pseudomonas aeruginosa* virulence: characterization of the AprA-AprI interface and species selectivity. *J Mol Biol.* (2012) 415:573–83. doi: 10.1016/j.jmb.2011.11.039
79. Imbert PR, Louche A, Luizet JB, Grandjean T, Bigot S, Wood TE, et al. A *Pseudomonas aeruginosa* TIR effector mediates immune evasion by targeting UBAP1 and TLR adaptors. *EMBO J.* (2017) 36:1869–87. doi: 10.15252/embj.201695343
80. Hickling TP, Sim RB, Malhotra R. Induction of TNF- α release from human buffy coat cells by *Pseudomonas aeruginosa* is reduced by lung surfactant protein A. *FEBS Lett.* (1998) 437:65–9. doi: 10.1016/S0014-5793(98)01200-9
81. Limoli DH, Rockel AB, Host KM, Jha A, Kopp BT, Hollis T, et al. Cationic antimicrobial peptides promote microbial mutagenesis and pathoadaptation in chronic infections. *PLoS Pathog.* (2014) 10:e1004083. doi: 10.1371/journal.ppat.1004083
82. Scott A, Weldon S, Buchanan PJ, Schock B, Ernst RK, McAuley DF, et al. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. *PLoS One.* (2011) 6:e26525. doi: 10.1371/journal.pone.0026525
83. Barbey-Morel C, Perlmutter DH. Effect of *pseudomonas* elastase on human mononuclear phagocyte alpha 1-antitrypsin expression. *Pediatr Res.* (1991) 29:133–40. doi: 10.1203/00006450-199102000-00005
84. Song KS, Kim HJ, Kim K, Lee JG, Yoon JH. Regulator of G-protein signaling 4 suppresses LPS-induced MUC5AC overproduction in the airway. *Am J Respir Cell Mol Biol.* (2009) 41:40–9. doi: 10.1165/rcmb.2008-0280OC
85. Grassme H, Kirschnek S, Riethmueller J, Riehle A, Von Kurthy G, Lang F, et al. CD95/CD95 ligand interactions on epithelial cells in host defense to *Pseudomonas aeruginosa*. *Science.* (2000) 290:527–30. doi: 10.1126/science.290.5491.527
86. Riquelme SA, Hopkins BD, Wolfe AL, Dimango E, Kitur K, Parsons R, et al. Cystic fibrosis transmembrane conductance regulator attaches tumor suppressor PTEN to the membrane and promotes anti *Pseudomonas aeruginosa* immunity. *Immunity.* (2017) 47: 1169–81.e7. doi: 10.1016/j.immuni.2017.11.010
87. Choi JK, Naffouje SA, Goto M, Wang J, Christov K, Rademacher DJ, et al. Cross-talk between cancer and *Pseudomonas aeruginosa* mediates tumor suppression. *Commun Biol.* (2023) 6:16. doi: 10.1038/s42003-022-04395-5
88. Kahle NA, Brenner-Weiss G, Overhage J, Obst U, Hansch GM. Bacterial quorum sensing molecule induces chemotaxis of human neutrophils via induction of p38 and leukocyte specific protein 1 (LSP1). *Immunobiology.* (2013) 218:145–51. doi: 10.1016/j.imbio.2012.02.004
89. Williams SC, Patterson EK, Carty NL, Griswold JA, Hamood AN, Rumbaugh KP. *Pseudomonas aeruginosa* autoinducer enters and functions in mammalian cells. *J Bacteriol.* (2004) 186:2281–7. doi: 10.1128/JB.186.8.2281-2287.2004
90. Ras GJ, Anderson R, Taylor GW, Savage JE, Van Niekirk E, Wilson R, et al. Proinflammatory interactions of pyocyanin and 1-hydroxyphenazine with human neutrophils in vitro. *J Infect Dis.* (1990) 162:178–85. doi: 10.1093/infdis/162.1.178
91. Manago A, Becker KA, Carpinteiro A, Wilker B, Soddemann M, Seitz AP, et al. *Pseudomonas aeruginosa* pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase. *Antioxid Redox Signal.* (2015) 22:1097–110. doi: 10.1089/ars.2014.5979
92. Pan X, Fan Z, Chen L, Liu C, Bai F, Wei Y, et al. PvrA is a novel regulator that contributes to *Pseudomonas aeruginosa* pathogenesis by controlling bacterial utilization of long chain fatty acids. *Nucleic Acids Res.* (2020) 48:5967–85. doi: 10.1093/nar/gkaa377
93. Koller B, Kappler M, Latzin P, Gaggari A, Schreiner M, Takay S, et al. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. *J Immunol.* (2008) 181:2753–63. doi: 10.4049/jimmunol.181.4.2753
94. Roy S, Karmakar M, Pearlman E. CD14 mediates Toll-like receptor 4 (TLR4). endocytosis and spleen tyrosine kinase (Syk). and interferon regulatory transcription factor 3 (IRF3). activation in epithelial cells and impairs neutrophil infiltration and *Pseudomonas aeruginosa* killing in vivo. *J Biol Chem.* (2014) 289:1174–82. doi: 10.1074/jbc.M113.523167
95. Barnes RJ, Leung KT, Schraft H, Ulanova M. Chromosomal gfp labelling of *Pseudomonas aeruginosa* using a mini-Tn7 transposon: application for studies of bacteria–host interactions. *Can J Microbiol.* (2008) 54:48–57. doi: 10.1139/w07-118
96. Yang JJ, Tsuei KC, Shen EP. The role of Type III secretion system in the pathogenesis of *Pseudomonas aeruginosa* microbial keratitis. *Tzu Chi Med J.* (2022) 34:8–14. doi: 10.4103/tcmj.tcmj_47_21
97. Aljohmani A, Opitz B, Bischoff M, Yildiz D. *Pseudomonas aeruginosa* triggered exosomal release of ADAM10 mediates proteolytic cleavage in trans. *Int J Mol Sci.* (2022) 23:1259. doi: 10.3390/ijms23031259
98. Forbes A, Davey AK, Perkins AV, Grant GD, McFarland AJ, McDermott CM, et al. ERK1/2 activation modulates pyocyanin-induced toxicity in A549 respiratory epithelial cells. *Chem Biol Interact.* (2014) 208:58–63. doi: 10.1016/j.cbi.2013.11.016
99. Gustke H, Kleene R, Loers G, Nehmann N, Jaehne M, Bartels KM, et al. Inhibition of the bacterial lectins of *Pseudomonas aeruginosa* with monosaccharides and peptides. *Eur J Clin Microbiol Infect Dis.* (2012) 31:207–15. doi: 10.1007/s10096-011-1295-x
100. Badaoui M, Zoso A, Idris T, Bacchetta M, Simonin J, Lemeille S, et al. Vav3 Mediates *Pseudomonas aeruginosa* adhesion to the cystic fibrosis airway epithelium. *Cell Rep.* (2020) 32:107842. doi: 10.1016/j.celrep.2020.107842
101. Gomez MI, Sokol SH, Muir AB, Soong G, Bastien J, Prince AS. Bacterial induction of TNF- α converting enzyme expression and IL-6 receptor α shedding regulates airway inflammatory signaling. *J Immunol.* (2005) 175:1930–6. doi: 10.4049/jimmunol.175.3.1930
102. Okuda J, Hayashi N, Okamoto M, Sawada S, Minagawa S, Yano Y, et al. Translocation of *Pseudomonas aeruginosa* from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator. *FXD3. Infect Immun.* (2010) 78:4511–22. doi: 10.1128/IAI.00428-10
103. Lassek C, Burghartz M, Chaves-Moreno D, Otto A, Hentschker C, Fuchs S, et al. A metaproteomics approach to elucidate host and pathogen protein expression during catheter-associated urinary tract infections (CAUTIs). *Mol Cell Proteomics.* (2015) 14:989–1008. doi: 10.1074/mcp.M114.043463
104. Faudry E, Job V, Dessen A, Attree I, Forge V. Type III secretion system translocator has a molten globule conformation both in its free and chaperone-bound forms. *FEBS J.* (2007) 274:3601–10. doi: 10.1111/j.1742-4658.2007.05893.x
105. Bainbridge T, Fick RB. Functional importance of cystic fibrosis immunoglobulin G fragments generated by *Pseudomonas aeruginosa* elastase. *J Lab Clin Med.* (1989) 114:728–33.
106. Wen L, Shi L, Kong XL, Li KY, Li H, Jiang DX, et al. Gut microbiota protected against *pseudomonas aeruginosa* pneumonia via restoring Treg/Th17 balance and metabolism. *Front Cell Infect Microbiol.* (2022) 12:856633. doi: 10.3389/fcimb.2022.856633
107. Kruczek C, Kottapalli KR, Dissanaik S, Dzvoza N, Griswold JA, Colmer-Hamood JA, et al. Major transcriptome changes accompany the growth of *Pseudomonas aeruginosa* in blood from patients with severe thermal injuries. *PLoS One.* (2016) 11:e0149229. doi: 10.1371/journal.pone.0149229
108. Elmassry MM, Mudaliar NS, Colmer-Hamood JA, San Francisco MJ, Griswold JA, Dissanaik S, et al. New markers for sepsis caused by *Pseudomonas aeruginosa* during burn infection. *Metabolomics.* (2020) 16:40. doi: 10.1007/s11306-020-01658-2
109. Barbieri JT. *Pseudomonas aeruginosa* exoenzyme S, a bifunctional type-III secreted cytotoxin. *Int J Med Microbiol.* (2000) 290:381–7. doi: 10.1016/S1438-4221(00)80047-8

110. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduct Target Ther.* (2022) 7:199. doi: 10.1038/s41392-022-01056-1
111. Sinha M, Ghosh N, Wijesinghe DS, Mathew-Steiner SS, Das A, Singh K, et al. *Pseudomonas aeruginosa* theft biofilm require host lipids of cutaneous wound. *Ann Surg.* (2023) 277:e634–47. doi: 10.1097/SLA.0000000000005252
112. Chadha J, Harjai K, Chhibber S. Revisiting the virulence hallmarks of *Pseudomonas aeruginosa*: a chronicle through the perspective of quorum sensing. *Environ Microbiol.* (2022) 24:2630–56. doi: 10.1111/1462-2920.15784
113. Jia J, Wang Y, Zhou L, Jin S. Expression of *Pseudomonas aeruginosa* toxin ExoS effectively induces apoptosis in host cells. *Infect Immun.* (2006) 74:6557–70. doi: 10.1128/IAI.00591-06
114. Arhin A, Boucher C. The outer membrane protein OprQ and adherence of *Pseudomonas aeruginosa* to human fibronectin. *Microbiology.* (2010) 156:1415–23. doi: 10.1099/mic.0.033472-0
115. Sugawara E, Nagano K, Nikaido H. Alternative folding pathways of the major porin OprF of *Pseudomonas aeruginosa*. *FEBS J.* (2012) 279:910–8. doi: 10.1111/j.1742-4658.2012.08481.x
116. Mishra M, Ressler A, Schlesinger LS, Wozniak DJ. Identification of OprF as a complement component C3 binding acceptor molecule on the surface of *Pseudomonas aeruginosa*. *Infect Immun.* (2015) 83:3006–14. doi: 10.1128/IAI.00081-15
117. Matsumoto K. Role of bacterial proteases in pseudomonal and serratal keratitis. *Biol Chem.* (2004) 385:1007–16. doi: 10.1515/BC.2004.131
118. Phuong MS, Hernandez RE, Wolter DJ, Hoffman LR, Sad S. Impairment in inflammasome signaling by the chronic *Pseudomonas aeruginosa* isolates from cystic fibrosis patients results in an increase in inflammatory response. *Cell Death Dis.* (2021) 12:241. doi: 10.1038/s41419-021-03526-w
119. Lee JH, Jeon J, Bai F, Wu W, Ha UH. Negative regulation of interleukin 1beta expression in response to DnaK from *Pseudomonas aeruginosa* via the PI3K/PDK1/FoxO1 pathways. *Comp Immunol Microbiol Infect Dis.* (2020) 73:101543. doi: 10.1016/j.cimid.2020.101543
120. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, Tirelli S, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. *Pediatr Pulmonol.* (2005) 40:15–21. doi: 10.1002/ppul.20237
121. Niarakis A, Laubenbacher R, An G, Ilan Y, Fisher J, Flobak Å, et al. Immune digital twins for complex human pathologies: applications, limitations, and challenges. *NPJ Syst Biol Appl.* (2024) 10:141. doi: 10.1038/s41540-024-00450-5